AIM Vaccine Co., Ltd.: Key Updates on R&D Project Suspensions and Asset Impairments
Summary of Announcement
AIM Vaccine Co., Ltd. released a supplemental announcement detailing significant financial and operational changes for the year ended December 31, 2025. The report highlights substantial impairment losses arising from the suspension of key R&D projects and delays in product commercialization, which may have direct impacts on shareholder value and share price.
Key Points of the Report
- Impairment Losses Recorded: The company has disclosed impairment losses on other intangible assets and property and equipment due to the suspension of R&D projects for both the mRNA human rabies vaccine and mRNA veterinary vaccine. Additionally, a delay in the commercialization timeline for the 13-valent pneumococcal conjugate vaccine (PCV13) contributed to these losses.
-
Suspension of mRNA Vaccine Projects:
- After evaluating domestic policy trends and project requirements, AIM Vaccine decided to temporarily suspend the advancement of its mRNA human rabies vaccine project, citing difficulties in obtaining clinical data from other mRNA vaccine products in the short term.
- The veterinary mRNA rabies vaccine project was also suspended due to significantly different market authorization pathways and requirements compared to the human vaccine. The company will focus on developing the human vaccine instead.
- These suspensions introduce significant uncontrollable uncertainties regarding the timing of R&D resumption, regulatory approval, commercialization timeline, and future economic benefits. There is no reliable basis to forecast future earnings from these projects.
- As a result, the management prudently excluded revenue contributions from these projects in its cash flow projections, reducing the valuation of deferred development costs from the acquisition by approximately RMB127.9 million.
-
Delay in PCV13 Commercialization:
- In December 2025, the company submitted an application to withdraw the NDA materials for PCV13 to the Center for Drug Evaluation, leading to a delay in commercialization.
- This delay, compounded by the need for supplemental studies, has significantly altered the market environment, competitive landscape, and future expected economic benefits.
- Projected revenues from PCV13 were reduced in the impairment test, and R&D expenses increased significantly. The valuation of development expenditures was reduced by approximately RMB83.23 million.
-
Impairment of Pneumococcal-Related Long-Term Assets:
- Due to the delay in PCV13 commercialization and impaired development expenditures, indications of impairment were found in related long-term assets.
- An impairment loss of RMB314.7 million was recognized for long-term assets related to the pneumonia vaccine, based on updated profitability forecasts.
- Board Update: The announcement was authorized by Chairman and CEO Mr. Yan ZHOU. The Board comprises several executive, non-executive, and independent non-executive directors.
Implications for Shareholders and Potential Share Price Impact
- The suspension of major mRNA vaccine projects and the delay of PCV13 commercialization represent significant setbacks for AIM Vaccine’s future revenue streams and overall business prospects.
- Large impairment losses (totaling over RMB525 million across deferred development costs and long-term assets) may materially affect the company’s financial position and profitability, and could negatively impact investor confidence.
- The uncertainties surrounding the resumption of R&D, regulatory approval, and commercialization timelines introduce substantial risks for shareholders, making future projections unreliable at this stage.
- The announcement contains highly price-sensitive information that could move the share price, given the scale of impairment and the strategic shift in R&D focus.
Disclaimer
This article is for informational purposes only and does not constitute investment advice. Investors are advised to conduct their own due diligence and consult with professional advisers before making investment decisions.
香港AIM疫苗有限公司：研發項目暫停及資產減值詳細公告
公告摘要
香港AIM疫苗有限公司就截至2025年12月31日的年度，發布補充公告，披露因研發項目暫停及產品商業化延遲導致重大財務及營運變動。這些變動可能對股東價值及股價產生直接影響。
報告重點
- 減值損失： 公司因mRNA人類狂犬病疫苗及mRNA獸用疫苗研發項目暫停，以及13價肺炎球菌結合疫苗（PCV13）商業化延遲，錄得其他無形資產及物業設備的減值損失。
-
mRNA疫苗項目暫停：
- 經評估國內政策趨勢及項目需求，AIM疫苗決定暫時停止mRNA人類狂犬病疫苗項目，因短期內難以獲得其他mRNA疫苗產品的臨床數據。
- 獸用mRNA狂犬病疫苗項目亦因審批路徑及要求差異較大而被暫停，公司將集中發展人類疫苗。
- 這些暫停導致研發恢復、審批、商業化時間及未來經濟效益出現重大不確定性，無法可靠預測未來收益。
- 管理層審慎將這些項目收入貢獻從現金流預測中剔除，令收購時遞延研發成本估值減少約人民幣1.279億元。
-
PCV13商業化延遲：
- 2025年12月，公司向藥品審評中心（CDE）提交撤回PCV13 NDA申請，導致商業化進程延遲。
- 延遲及補充研究需求，令市場環境、競爭格局及預期經濟效益發生重大變化。
- 管理層在減值測試時調低項目收入預測，研發支出顯著增加，研發支出估值減少約人民幣8323萬元。
-
肺炎球菌相關長期資產減值：
- 因PCV13商業化延遲及研發支出減值，管理層認為相關長期資產存在減值跡象。
- 根據最新盈利預測，肺炎疫苗相關長期資產錄得人民幣3.147億元減值損失。
- 董事會更新： 公告由董事會主席兼行政總裁周炎先生授權，董事會成員包括多位執行、非執行及獨立非執行董事。
對股東及股價的影響
- 主要mRNA疫苗研發項目暫停及PCV13商業化延遲，對公司未來收入及業務前景構成重大打擊。
- 巨額減值損失（合共逾人民幣5.25億元）將實質影響公司財務狀況及盈利能力，或削弱投資者信心。
- 研發恢復、審批及商業化時間的不確定性，令股東面臨重大風險，未來預測現階段無法作出。
- 公告內資訊屬高敏感性，可能對股價造成重大波動。
免責聲明
本文僅供參考，不構成投資建議。投資者應自行進行盡職調查及咨詢專業顧問後作出投資決定。
